Datapoint: FDA Pushes Back Xeljanz Review Again

The FDA has again delayed its review of Pfizer’s Xenjanz in ankylosing spondylitis, according to a news release from the drugmaker. The JAK inhibitor was previously found to increase the risks of serious heart problems and certain cancers compared to rheumatoid arthritis patients on TNF inhibitors. For the treatment of rheumatoid arthritis, Xeljanz currently holds covered or better status for 73% of all insured lives under the pharmacy benefit. 50.7% of covered lives have preferred access to Xeljanz, with utilization management restrictions applied in most cases.

SOURCE: MMIT Analytics, as of 7/26/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 26

Datapoint: Elevance Health to Acquire BCBS Louisiana

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 25

Datapoint: Seagen Scores Colorectal Cancer Nod for Tukysa

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 24

Datapoint: Georgia Doubles Down on Partial Medicaid Expansion Waiver

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today